New Zealand markets closed

Precision BioSciences, Inc. (DTIL)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
9.88-0.05 (-0.50%)
At close: 04:00PM EDT

Precision BioSciences, Inc.

302 East Pettigrew Street
Suite A-100
Durham, NC 27701
United States
919 314 5512

Full-time employees109

Key executives

NameTitlePayExercisedYear born
Mr. Michael AmorosoPresident, CEO & Director1.07MN/A1978
Mr. John Alexander Kelly R.Ph.CFO & Principal Accounting Officer660.91kN/A1967
Dr. Alan F. List M.D.Chief Medical Officer692.17kN/A1955
Dr. Jefferson J. Smith Ph.D.Co-Founder & Chief Research OfficerN/AN/A1973
Mei BurrisDirector of Investor Relations & FinanceN/AN/AN/A
Mr. Dario ScimecaGeneral Counsel & Secretary576.43kN/A1975
Mr. Bruce StevensVice President of Quality & ComplianceN/AN/AN/A
Maurissa MessierSenior Director of Corporate CommunicationsN/AN/AN/A
Ms. Juli BlancheChief People OfficerN/AN/AN/A
Mr. Garrett GincleyHead of ManufacturingN/AN/AN/A
Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Precision BioSciences, Inc., an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA. In addition, it develops PBGENE-NVS for sickle cell disease/beta thalassemia for insertion; PBGENE-DMD (excision) for duchenne muscular dystrophy; PBGENE-LL2 (insertion), a liver directed target; PBGENE-LL3, a central nervous system directed target; and iECURE-OTC (insertion) for ornithine transcarbamylase deficiency. The company has license and collaboration agreement with Caribou Biosciences, Inc.; license agreement with TG Cell Therapy, Inc. to develop, manufacture, and commercialize azer-cel for autoimmune diseases and other indications outside of cancer; development and license agreement with Eli Lilly and Company for the research and development of potential in vivo therapies for genetic disorders; Cellectis S.A.; iECURE, Inc. to develop ARCUS-based gene-insertion therapies; Duke University; and Novartis Pharma AG to discover and develop in vivo gene editing products. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.

Corporate governance

Precision BioSciences, Inc.’s ISS governance QualityScore as of 1 July 2024 is 7. The pillar scores are Audit: 2; Board: 6; Shareholder rights: 9; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.